endometrial-cancer

HER2-targeted antibody-drug conjugate shows 70% response rate in advanced endometrial cancer.

Advanced or metastatic endometrial cancer with HER2 expression has limited treatment options. Phase II trial data reported at the Society of Gynecologic Oncology (SGO) meeting showed that an investigational antibody-drug conjugate (ADC)—trastuzumab deruxtecan—achieved response rates of up to 70% in…

cervical-cancer

Deep learning automates organ contouring for brachytherapy—works even with interstitial needles in place.

Three-dimensional image-guided brachytherapy (3D-IGBT) for cervical and endometrial cancer requires precise contouring of organs at risk (OARs: bladder, small bowel, rectum, sigmoid) for treatment planning. Manual contouring is time-consuming and variable. This study developed and tested a deep…